Tissue-resident Immune Cell Subsets in aGVHD

Recruiting now

Conditions studied: Acute Graft-versus-Host Disease, Hematopoietic Stem Cell Transplantation

In brief

This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).

Key facts

Study ID

NCT06708507

Run by

Nanfang Hospital, Southern Medical University

People needed

40

Starts

2024-11-16

Expected to finish

2025-05-31

Last updated by the study team

2024-11-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Voluntarily sign the informed consent form;
• Age 16-65 years old
• Clinically diagnosed with GVHD for the first time/receiving GVHD treatment.

You may not qualify if…

• Have a history of other tumors
• With poor compliance or mental disorders
• Infected with HIV and HCV
• With uncontrolled HBV infection
• With other autoimmune diseases
• Those who are judged by the researcher to be unsuitable to participate in this study

Where it is running

• Nanfang Hospital, Southern Medical University — Guangzhou, Other (Non U.s.), China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.